Recent Updates
Recently added Catalysts

sevelamer carbonate, sevelamer

Phase 3

Chronic Kidney Disease | Small molecule | Nephrology |Sanofi|Last Updated: Mar 23, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials3
Total Enrollment334
FDA Designations
No designations recorded
Clinical Trials (3)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01736150Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on HemodialysisPHASE3 COMPLETED 205Mar 1, 2010Sep 1, 2010Mar 23, 201518 China
NCT00681941An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On DialysisPHASE3 COMPLETED 49Jan 1, 2006Mar 1, 2007Mar 20, 201525 Australia, Denmark +3
NCT00440648Cross-Over Study of Sevelamer Hydrochloride and Sevelamer CarbonatePHASE2 COMPLETED 80Mar 1, 2005Jul 1, 2006Mar 19, 201415 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change from baseline to Visit 6/Early Termination (ET) in serum phosphorous.
8 weeks
Frequency of treatment-emergent adverse events (AEs) and serious adverse events (SAEs), changes in laboratory parameters, and changes in vital signs.
11 weeks
Evaluate the efficacy of sevelamer carbonate tablets dosed three times per day (TID) with meals on control of serum phosphorus levels
Up to day 70
Evaluate the safety and tolerability of sevelamer carbonate tablets dosed TID with meals.
Up to day 70
Safety-evaluated on the basis of adverse events (reported and/or observed)
16 weeks
changes in laboratory parameters, vital signs
16 weeks
note: clinically significant changes in physical examination were recorded and evaluated as adverse events
16 weeks
Efficacy-treatment regimens are compared on the basis of serum phosphorus at the end of each treatment period using the time-weighted mean of the phosphorus value from the last three visits in each treatment period
16 weeks
Treatment regimens were also compared with respect to total, LDL, and HDL cholesterol, and triglycerides, using the mean of values for each parameter from the two post-baseline assessments in each treatment period.
16 weeks
Secondary Endpoints
Change from baseline to Visit 6/ET in serum lipids (total cholesterol and LDL-cholesterol).
8 weeks
Serum calcium-phosphorus product
Up to day 70
Serum lipid profile [total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol]
Up to day 70
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Sevelamer carbonateEXPERIMENTALSubjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (\>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
PlaceboPLACEBO_COMPARATORSubjects randomized by a central randomization system to one of two treatment groups in a 2:1 (active: placebo) fashion, stratified by Visit 1a phosphorus result (\>5.5 mg/dL-6.5 mg/dL versus greater than 6.5 mg/dL), and site.
1EXPERIMENTALSevelamer Carbonate Tablets Dosed Three Times A Day
2OTHERsevelamer hydrochloride w(1-8) sevelamer carbonate w(9-16)
Interventions
NameTypeDescription
PlaceboDRUG* Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals. * If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals.
Sevelamer carbonateDRUG* Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals. * If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals.
Sevelamer carbonate (Renvela®)DRUGSevelamer Carbonate Tablets Dosed Three Times A Day
sevelamer carbonate, sevelamer hydrochlorideDRUGStarting dose individualized for each patient and fixed daily dose throughout both treatment periods
sevelamer hydrochloride, sevelamer carbonateDRUGStarting dose individualized for each patient and fixed daily dose throughout both treatment periods
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites18

Inclusion Criteria: * On hemodialysis regimen scheduled for four hour duration three times per week for a minimum 30 days prior to Visit 1 and throughout the study * Have a central laboratory serum iPTH measurement less than 1000 pg/mL at Visit 1 * Have a central laboratory serum phosphorus measure...

Countries:ChinaAustraliaDenmarkFranceGermanyUnited KingdomUnited States
Unlock Eligibility Criteria